GlassScriptPhysician profile
Swarnjit Singh
NPI 1134128069
$1,688.23
in general payments reported to CMS, 2019-2025
16 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $115 · 2021: $256 · 2022: $414 · 2023: $307 · 2024: $183 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.00 | 2021-2025 | Rinvoq |
| Gilead Sciences, INC. | $274.65 | 2021-2025 | |
| Celgene Corporation | $249.81 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $181.78 | 2019-2022 | |
| Pfizer INC. | $120.19 | 2019 | |
| Genzyme Corporation | $76.81 | 2025 | |
| Organon LLC | $59.84 | 2023-2024 | Hadlima, Renflexis |
| Medtronic, INC. | $35.13 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.47 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.43 | 2023 | Entyvio |
| Redhill Biopharma INC. | $20.97 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.29 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $16.52 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.09 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.25 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,879.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swarnjit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.